TABLE 3.
Incidence, n (%) | Gla‐300 (N = 172) | IDeg‐100 (N = 171) |
---|---|---|
Any TEAE | 50 (29.1) | 35 (20.5) |
Any treatment‐emergent SAE | 7 (4.1) | 8 (4.7) |
Any TEAE leading to death | 0 | 0 |
Any TEAE leading to permanent treatment discontinuation | 0 | 0 |
Any treatment‐related TEAE | 4 (2.3) | 7 (4.1) |
Abbreviations: Gla‐300, insulin glargine 300 U/ml; IDeg‐100, insulin degludec 100 U/ml; SAE, serious adverse event; TEAE, treatment‐emergent adverse event.